JP2024023349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023349A5 JP2024023349A5 JP2023196825A JP2023196825A JP2024023349A5 JP 2024023349 A5 JP2024023349 A5 JP 2024023349A5 JP 2023196825 A JP2023196825 A JP 2023196825A JP 2023196825 A JP2023196825 A JP 2023196825A JP 2024023349 A5 JP2024023349 A5 JP 2024023349A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- composition
- compound
- peg
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 235000012000 cholesterol Nutrition 0.000 claims 7
- 150000003904 phospholipids Chemical class 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 150000001412 amines Chemical group 0.000 claims 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 229940125898 compound 5 Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025282870A JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277262P | 2016-01-11 | 2016-01-11 | |
| US62/277,262 | 2016-01-11 | ||
| US201662420258P | 2016-11-10 | 2016-11-10 | |
| US62/420,258 | 2016-11-10 | ||
| US201762444172P | 2017-01-09 | 2017-01-09 | |
| US62/444,172 | 2017-01-09 | ||
| JP2018554659A JP6918829B2 (ja) | 2016-01-11 | 2017-01-11 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2021120731A JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021120731A Division JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025282870A Division JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023349A JP2024023349A (ja) | 2024-02-21 |
| JP2024023349A5 true JP2024023349A5 (https=) | 2024-05-24 |
Family
ID=59311885
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554659A Active JP6918829B2 (ja) | 2016-01-11 | 2017-01-11 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2021120731A Active JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2023196825A Pending JP2024023349A (ja) | 2016-01-11 | 2023-11-20 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2025282870A Pending JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554659A Active JP6918829B2 (ja) | 2016-01-11 | 2017-01-11 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
| JP2021120731A Active JP7439023B2 (ja) | 2016-01-11 | 2021-07-21 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025282870A Pending JP2026053650A (ja) | 2016-01-11 | 2025-12-25 | 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10570119B2 (https=) |
| EP (3) | EP3402532B1 (https=) |
| JP (4) | JP6918829B2 (https=) |
| KR (2) | KR102558501B1 (https=) |
| CN (2) | CN108697811B (https=) |
| AU (3) | AU2017207299B2 (https=) |
| DK (2) | DK3936153T3 (https=) |
| ES (2) | ES2997263T3 (https=) |
| FI (1) | FI3936153T3 (https=) |
| HR (1) | HRP20241512T1 (https=) |
| IL (2) | IL313681A (https=) |
| MA (1) | MA43870A (https=) |
| MX (1) | MX2018008507A (https=) |
| PL (1) | PL3402532T3 (https=) |
| PT (1) | PT3936153T (https=) |
| SI (1) | SI3936153T1 (https=) |
| WO (1) | WO2017123588A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018008507A (es) * | 2016-01-11 | 2019-07-04 | Merrimack Pharmaceuticals Inc | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). |
| TWI755629B (zh) * | 2018-09-13 | 2022-02-21 | 台灣微脂體股份有限公司 | 含鎮靜藥物之緩釋藥物組合物及其用途 |
| JP7477844B2 (ja) * | 2018-10-17 | 2024-05-02 | タイワン リポソーム カンパニー リミテッド | 免疫調節剤を含む徐放性医薬組成物およびその使用 |
| US20230190752A1 (en) * | 2020-05-07 | 2023-06-22 | Washington University | Compositions and methods for predicting therapeutic outcome |
| CA3183397A1 (en) | 2020-06-18 | 2021-12-23 | Daryl C. Drummond | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
| CA3190273A1 (en) * | 2020-09-14 | 2022-03-17 | Qun Sun | Formulations of cabazitaxel |
| AU2021360636A1 (en) | 2020-10-16 | 2023-06-15 | Shanghai De Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
| TW202508589A (zh) * | 2023-07-14 | 2025-03-01 | 美商爵士製藥股份有限公司 | 包含ａｔｒ抑制劑及ｐａｒｐ抑制劑之組合及其使用方法 |
| KR20260049706A (ko) * | 2023-07-14 | 2026-04-14 | 재즈 파마슈티컬스 테라퓨틱스, 인크. | Atr 억제제를 포함하는 리포좀 조성물의 사용 방법 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4990610A (en) | 1988-08-25 | 1991-02-05 | Applied Analytical Industries, Inc. | Method for preparing high potency sucralfate |
| US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004080982A1 (en) | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| GB0411401D0 (en) | 2004-05-21 | 2004-06-23 | Tissuomics Ltd | Penetrating radiation measurements |
| EP1778648A2 (en) * | 2004-08-19 | 2007-05-02 | ICOS Corporation | Compounds useful for inhibiting chk1 |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
| JP5277168B2 (ja) | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| EP3494964B1 (en) | 2007-05-14 | 2021-04-07 | Konica Minolta Holdings, Inc. | Liposome and method for producing liposome |
| CA2743134A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP5951994B2 (ja) | 2008-12-19 | 2016-07-13 | イマージョン コーポレーションＩｍｍｅｒｓｉｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | 対話型ペインティングゲーム及び関連するコントローラ |
| ES2921576T3 (es) * | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| US20110053923A1 (en) * | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| CA2772989A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| CA2798760A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
| CN102485212B (zh) * | 2010-12-01 | 2014-04-09 | 沈阳药科大学 | 苹果酸舒尼替尼脂质体及其制备方法 |
| CN102485213A (zh) * | 2010-12-01 | 2012-06-06 | 沈阳药科大学 | 伊立替康脂质体及其制备方法 |
| MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| CN108685922A (zh) | 2011-09-30 | 2018-10-23 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013049722A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN106496173A (zh) | 2011-09-30 | 2017-03-15 | 沃泰克斯药物股份有限公司 | 用于制备可用作atr激酶抑制剂的化合物的方法 |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2015502925A (ja) * | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 |
| CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| EP2909202A1 (en) * | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| MX2018008507A (es) * | 2016-01-11 | 2019-07-04 | Merrimack Pharmaceuticals Inc | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). |
-
2017
- 2017-01-11 MX MX2018008507A patent/MX2018008507A/es unknown
- 2017-01-11 CN CN201780011422.0A patent/CN108697811B/zh active Active
- 2017-01-11 WO PCT/US2017/012939 patent/WO2017123588A1/en not_active Ceased
- 2017-01-11 EP EP17738831.1A patent/EP3402532B1/en active Active
- 2017-01-11 ES ES21182826T patent/ES2997263T3/es active Active
- 2017-01-11 PT PT211828264T patent/PT3936153T/pt unknown
- 2017-01-11 DK DK21182826.4T patent/DK3936153T3/da active
- 2017-01-11 JP JP2018554659A patent/JP6918829B2/ja active Active
- 2017-01-11 AU AU2017207299A patent/AU2017207299B2/en active Active
- 2017-01-11 DK DK17738831.1T patent/DK3402532T3/da active
- 2017-01-11 HR HRP20241512TT patent/HRP20241512T1/hr unknown
- 2017-01-11 SI SI201731565T patent/SI3936153T1/sl unknown
- 2017-01-11 IL IL313681A patent/IL313681A/en unknown
- 2017-01-11 US US16/069,092 patent/US10570119B2/en active Active
- 2017-01-11 FI FIEP21182826.4T patent/FI3936153T3/fi active
- 2017-01-11 MA MA043870A patent/MA43870A/fr unknown
- 2017-01-11 CN CN202310263334.7A patent/CN116211803B/zh active Active
- 2017-01-11 PL PL17738831.1T patent/PL3402532T3/pl unknown
- 2017-01-11 ES ES17738831T patent/ES2921008T3/es active Active
- 2017-01-11 KR KR1020227037451A patent/KR102558501B1/ko active Active
- 2017-01-11 EP EP24194804.1A patent/EP4438127A3/en active Pending
- 2017-01-11 EP EP21182826.4A patent/EP3936153B1/en active Active
- 2017-01-11 IL IL260487A patent/IL260487B2/en unknown
- 2017-01-11 KR KR1020187022169A patent/KR102461219B1/ko active Active
-
2020
- 2020-01-17 US US16/745,709 patent/US11028076B2/en active Active
-
2021
- 2021-05-07 US US17/314,753 patent/US11787781B2/en active Active
- 2021-07-21 JP JP2021120731A patent/JP7439023B2/ja active Active
-
2023
- 2023-09-01 US US18/460,047 patent/US20230416236A1/en not_active Abandoned
- 2023-11-20 JP JP2023196825A patent/JP2024023349A/ja active Pending
- 2023-12-15 AU AU2023282309A patent/AU2023282309B2/en active Active
-
2024
- 2024-11-07 US US18/940,070 patent/US20250333396A1/en active Pending
-
2025
- 2025-12-09 AU AU2025279601A patent/AU2025279601A1/en active Pending
- 2025-12-25 JP JP2025282870A patent/JP2026053650A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023349A5 (https=) | ||
| US6586559B2 (en) | Polyamide oligomers | |
| US6056938A (en) | Cationic lipids and the use thereof | |
| JP3571335B2 (ja) | リポゾームマイクロレシーバー組成物および方法 | |
| JP2005504749A5 (https=) | ||
| US20130216607A1 (en) | Zwitterionic lipids | |
| JP2001527052A5 (https=) | ||
| JP3631755B2 (ja) | ポリオキシエチレン含有脂質二本鎖誘導体 | |
| AU751434B2 (en) | Polyamide oligomers | |
| JP2004511572A (ja) | 標的化送達のための脂質製剤 | |
| JP2020519625A5 (https=) | ||
| PT742789E (pt) | Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao | |
| JP2024540101A5 (https=) | ||
| BR112014022847B1 (pt) | Lipídios aminoácidos, composição vesicular, e kit | |
| JPH08510748A (ja) | リポソームが誘発する生理的副作用の低減 | |
| IL313681A (en) | Inhibiting ataxia telangiectasia and rad3-related protein (atr) | |
| JP2005505521A5 (https=) | ||
| JP2026503201A5 (https=) | ||
| JP4723097B2 (ja) | サイトフェクチン二量体およびその使用方法 | |
| CN1088582C (zh) | 能治疗多种疾病具有层状类脂组分的类脂基载体、其组合物及其应用 | |
| US20040213835A1 (en) | Method to reduce liposome-induced complement activation | |
| WO2001074333A1 (en) | D and l etherlipid stereoisomers and liposomes | |
| BRPI0717800A2 (pt) | COMPOSIÇÃO DE LIPOSSOMAS SENSÍVEIS AO pH | |
| JPWO2023054241A5 (https=) | ||
| US7008614B2 (en) | Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome |